Post Reply
8061-8080 of 10899
Sine my last post, BIG has survived last week without dropping below the recent support line bordering at around 0.73 cents.
Looking at the volume transacted on 22nd jan, 23rd jan, 24th jan, last week totalling approx 60m, the majority of contra players who bought the shares would have come out by yesterday.
It looks increasing likely that BIG will hold above current levels (ie at 0.73), and hopfully stay above the recent low of 0.69 cents, which was achieved on dec 18th 2007.
On the fundamental front, some facts to get you thinking about the possible revenues that BIG can generate from the CE Mark going forward.
Conors Medsystem got the CE mark on 18th Feb 2006.
Their Q106 revenue for their DES was US$4.4m (approx 1 and half mths). Their Q206 revenue was US$11.3m and Q306 revenue wasUS$10.7m.
THey achieved an average of US$40-45m revenue annualised over a year.
In Medtronics last Q307 annoucement, they achieve a revenue of US$80m for their Endeavour stent (just with the CE mark alone), an increase of 10 % Quarter -on- Quarter. Annualised, they are making US$320m per year..
If you were to project the potential revenue for BIG, based on the 2 CE marks that they have got (for themselves and Terumo), It looks likely to come in somewhere in between Conor's lower end of US$40m and Medtronics US$320m.
Some facts to set you thinking -Not a call to buy or sell.
Bengster,
Can highlight the Biosensor role or involvement in the article? Thanks.
This last posting is the one reported in Oct 2007. Looks like BIG is far superior. Am surprised you can get all this info and the analyst can't????
Medtronic presents Endeavor trial results, industry responds
|
 |
 |
 |
| |
<>
| Oct 25, 2007 at 04:34 PM |
 |
|
| Source: Medtronic |
|
In anticipation of receiving FDA approval by year?s end for its Endeavor drug-eluting stent (DES), Medtronic presented its Endeavor IV clinical trial findings this week at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. In response, a panel of cardiologists questioned the methods of the study and discussed the safety of the stent.
The ?drug release [of Endeavor?s Zotarolimus] is more rapid? than its competitors, Cordis and Boston Scientific, because ?most of the drug is released in 14 days,? said
Martin Leon, MD, of Columbia Medical Center in New York City who represented on Medtronic?s behalf. He did, however, concede that Endeavor ?needs more and longer studies.?
The Endeavor IV clinical trial included 1,548 patients, 773 of which had the Endeavor stent implanted, and the other 775 who had the Boston Scientific?s Taxus stent implanted, according to Leon. The vessel diameter was between 2.5mm and 3.5mm. The primary endpoint for the study is target vessel failure (TVF) at nine months. The secondary endpoints included the target vessel revascularization (TVR) and target lesion revascularization (TLR) at nine months.
Of 144 patients who received an Endeavor stent, 19 patients, or 13.3 percent, had an occurrence of in-stent restenosis. For 135 patients with the Taxus stent, nine patients, or 6.7 percent, had an occurrence of in-stent restenosis.
Leon reported that the primary endpoint at nine months for TVF was 6.6 percent for Endeavor and 7.2 percent for Taxus. He said there was significant TVF difference at 12 months, but ?Endeavor?s results remain lower.?
For the secondary endpoints, 5.4 percent of the patients with Endeavor at nine months experienced TVR while 4.9 percent of patients with Taxus experienced TVR at nine months. For the Endeavor results, 4.1 percent of patients experienced TLR at nine months with Endeavor, while 2.7 percent of patients with Taxus experienced TLR.
In addition, two patients implanted with the Endeavor stent died, while no patients implanted with Taxus died. Leon stressed that these deaths were not attributed to the stent.
Leon concluded that Endeavor reduced peri-procedural complications, and Endeavor?s statistics were similar to Taxus in its overall safety profile for larger complications such as death and myocardial infarctions (MI).
In response to Leon?s presentation, Patrick Serruys, MD, chief of interventional cardiology at Thoraxcenter-Erasmus University in Rotterdam, Netherlands, said that the Endeavor study had ?obvious conflicts,? and questioned the methodologies of the study.
Serruys said Endeavor met its non-inferiority primary endpoint of TVF at nine months in comparison to the Taxus stent. However, Serruys disagreed with that method of TVF as a sole primary endpoint, because he believed the primary endpoint should be a composite of TVR, death and MI as well.
Serruys cited data from a European clinical study, which consisted of 1,490 patients, 749 of which had Endeavor implanted and 741 of which had Taxus. In overall cardiac-related deaths, four patients died for each of the stents. Two Endeavor patients had a Q-wave MI, and only one with Taxus. In Endeavor patients, 34 experienced TLR, 47 experienced TVR and 50 experienced TVF. In comparison, with Taxus patients, 24 experienced TLR, 50 experienced TVR and 47 experienced TVF.
In a different Swedish Coronary Angiography and Angioplasty Registry study, out of 2,497 patients, Endeavor had the highest rate of restenosis, followed by Taxus, according to Serruys.
In conclusion, Serruys reiterated his skepticism of about Endeavor?s efficacy.
In a panel discussion of six cardiologists that immediately followed the presentations, the physicians discussed whether Endeavor is safer. According to Jean Marco, MD, of Clinique Pasteur in Toulouse, France, who is currently implementing the CE Mark-approved Endeavor said it is ?similar in safety to other stents.? Alexandra Lansky, MD, a clinical cardiologist at NewYork-Presbyterian Hospital/Columbia Medical Center in New York City, said that for ?low risk patients, the device is safe, but it becomes more questionable for more complex patients.? Giulio Guagliumi, MD, of Ospedali Riuniti di Bergamo in Bergamo, Italy, said ?we still have to collect big numbers.? He added that he ?was little a surprised that stent thrombosis isn?t lower than Taxus. While six incidents in Endeavor and one in Taxus isn?t statistically significant, but there are still more.?
The panel also discussed the difference in the clinical efficacy of Endeavor, in particular with TLR. Mitchell Krucoff, MD, an interventional cardiologist at Duke University Medical Center in Durham, N.C., said there is an ?anatomic change, and where it becomes a clinical threshold is still to be determined.? Krucoff noted that it is a question of numbers, but said ?it doesn?t concern me about late loss in Endeavor.? Serruys reiterated his initial message by stating that ?when the stent faces the real world, and the number of interventions will increase, that is my concern.?
The moderator asked the panelists if they will use Endeavor. Serruys said he does not think he will use it. Alan Yeung, MD, chief of the cardiology at Harvard Medical School, said ?in patients with large vessels, I might consider using the Endeavor stent.? Marco said that at his hospital, ?we use this stent in 100 percent of our patients.?
Despite some disagreements on methodology, the entire panel reached consensus that more investigation into the Endeavor stent needs to be conducted.
|
My estimated results for BIG's 3rd quarter FY2008 is US$8m loss.
Medtronic wins FDA approval for drug-coated stent
CHICAGO (Reuters) - U.S. health regulators on Friday approved Medtronic Inc's new drug-eluting heart stent, the first heart device of its kind to win U.S. approval in about 4 years.
Medtronic will join Johnson & Johnson and Boston Scientific Corp as the manufacturers of the only such heart devices -- which pop open diseased heart arteries and deliver medicine to keep them from reclosing -- approved in the U.S.
But the tiny wire mesh tubular device that Medtronic calls Endeavor may face a far less welcoming reception from physicians than its predecessors as it enters a market clouded by controversy.
The market for the drug-coated variety of stents has fallen from a peak of around $6 billion in recent years over safety concerns about blood clots forming long after implantation in some patients.
Medtronic estimates the global market for the devices now stands at about $4 billion.
The Minneapolis-based company, which also makes pacemakers and insulin pumps, is billing Endeavor as a safer stent.
An FDA advisory panel in October recommended approval of the device, saying it appeared safe and effective based on current data. The panel also recommended the company commit to a large follow-up study to monitor the blood clotting issue.
Drug-coated stents were hailed as a major medical advance in 2003, when J&J's device was approved and the newer generation rapidly replaced cheaper and older bare-metal stents in many uses. The popularity stemmed from the drug coating's ability to cut the incidence of reclogging.
But the emergence of an increased risk of late-stage blood clotting, known as thrombosis, led some doctors to switch back to bare-metal stents.
Still another large study, released late last year, suggested that patients who received drug-coated stents were not more likely to die or suffer heart attacks than those who got bare-metal versions, fanning the debate further.
Should clotting, in fact, be less of an issue, then Endeavor might have trouble finding a niche, according to Debbie Wang, a Morningstar analyst. ***(Endeavor has one of the worst short term DES performance)
"That kind of cuts the leg out from under Medtronic's whole marketing platform, suggesting that this is the safer stent," she said. "I just don't know there is really a nice niche for the Endeavor stent to slide into."
But, she added, having a new device is going to help Medtronic.
"Interventional cardiologists tend to be gadget junkies. I'm sure they will be a number of them who are eager to try out this new stent," she said.
Medtronic said it will begin selling the Endeavor stent immediately and will ship some 100,000 to U.S. hospitals in the next 30 days.
Abbott Laboratories Inc is awaiting an FDA decision for its drug-coated stent, Xience. Analysts expect approval during the second quarter.
Mike Weinstein, an analyst with JP Morgan, reckons Medtronic's market share will likely approach 20 percent in the interim period before Abbott's Xience is launched, slipping to the mid-teens thereafter.
Medtronic shares were up $1.08 or 2.3 percent to $47.65 on the New York Stock Exchange.
*** Wait until late-thrombosis cases start appearing for Endeavor and MDT's whole marketing platform revolving around "safer stent" will collapse. We know Endeavor has the weakest short term DES benefit due to zotarolimus drug having the least drug potency. Endeavor has no other strong performance highlights (no other good selling points) except no media reports on their late-thrombosis so far. If late-thrombosis incidents start appearing for Endeavor, then this DES is even worse than first generation DES like Cypher. Endeavor uses durable polymer after all. With only a few hundred patients with 3 years data with no late-thrombosis and MDT can claim Endeavor is the safest DES around??? We shall wait and see.
Thanks Bengster. Looks loke action on Monday...Ayo we break for Chinese New Year on Thursday? Wednesday half day???
When Will Docs Reach for Medtronic?s Endeavor Stent?
Posted by Jacob Goldstein
The FDA just greenlighted
Medtronic?s Endeavor drug-coated stent. That means there are now three manufacturers (Boston Scientific and J&J are the other two) fighting for a coated-stent market that?s been
battered by safety concerns and accusations of over-use.
And before you start dividing that battered market by three, recall that Abbott?s probably going to get in on the action shortly, assuming the FDA follows everybody?s expectations and
approves the Xience stent.
So how will the new stents compete against the old ones? Docs like to stay with what they know ? in this case, JNJ?s Cypher and Boston Scientific?s Taxus stent, Joseph DeGregorio, Director of Interventional Cardiology at Hackensack University Medical Center, told the Health Blog. But the word on the street is that the new stents are easier to put into tight spots, he said.
?A lot of the cases we do are not complicated and you can deliver any stent you want,? DeGregorio said. ?When you?ve had a proven product out there that you?re comfortable with, you?re gonna stick with that.?
The new stents may find a sizable foothold in the 20% to 30% of cases where doctors want to put the stent in some especially hard-to-get-to place, according to DeGregorio, who said he has financial ties to all of the stent makers. Because of factors such as the profile of the delivery package, the new stents from Abbott and Medtronic may work better in those cases.
?I have to get my hands on it,? he said of the Endeavor. ?I have to see what I think about the deliverability, which I?ve heard is better? [If] I couldn?t get in a Cypher or Taxus, I might use this stent.?
*** Doctors are "keng" kings also. Stent deliverability seems to be the top in their list of considering which DES to use. As long as their angioplasty job is done, any future problems is not the doctor's problems since they did their job already. Blame FDA or the medical device companies if the patients have late-thrombosis problems. All the DESs are approved for use anyway so the doctors will use whichever one that gives them the best "commission/loyalty program" package and ease of performing their surgery job.
UK agency ends blanket opposition to drug stents
LONDON, Feb 1 (Reuters) - In a change of tack, Britain's healthcare cost-effectiveness agency has proposed that drug-coated stents -- used to prop open clogged coronary arteries -- should continue to be given on the state-run National Health Service to some high-risk patients.
The National Institute for Health and Clinical Excellence (NICE) caused a storm last August when it gave an opinion that drug-coated, or eluting, stents were not worth the extra cost compared with older bare metal ones.
The final draft guidance issued on Friday, however, states they are suitable for patients who are at higher risk of needing further stents if a bare one were used instead.
NICE said more expensive drug stents were appropriate when a coronary artery was less than 3mm in diameter, or the segment of the artery to be treated was longer than 15mm. Such lesions are particularly tricky to treat.
The new guidance also states drug stents should only be used if the price difference with bare metal ones is no more than 300 pounds ($595).
That could put pressure on prices of some products, since NICE said a sample of prices paid by health authorities in 2007 and 2008 showed the actual cost difference between the two types ranged from 203 to 615 pounds.
Drug-coated versions of stents -- tiny, wire-mesh tubes that are inserted into arteries -- are a multibillion-dollar global business for companies like Boston Scientific (BSX.N:
Quote,
Profile,
Research), Johnson & Johnson (JNJ.N:
Quote,
Profile,
Research), Medtronic (MDT.N:
Quote,
Profile,
Research) and Abbott Laboratories (ABT.N:
Quote,
Profile,
Research).
But their use has fallen sharply in the past year and a half on concerns they may sometimes cause blood clots.
The NICE recommendations could have widespread implications, since the agency has led the world in assessing the value of new treatments and its actions are closely watched by other governments and insurers, particularly in Europe.
Since 1999, NICE has been responsible for determining which treatments should be reimbursed on the state health service in England and Wales.
Morgan Stanley had earlier predicted a NICE recommendation against using drug stents could trigger a 13-15 percent European price cut, reducing the size of the market by $102 million, or 5 percent in 2008.
The new proposals have not yet been issued as guidance to Britain's state health service, and companies and other stakeholders have until Feb. 15 to lodge an appeal.
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in FranceFriday February 1, 5:00 am ET
- Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority
ABBOTT PARK, Illinois, February 1 /PRNewswire/ -- Abbott (NYSE:
ABT -
News) today announced that it has received reimbursement approval in France for its XIENCE(TM) V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug eluting stent in a randomized clinical trial.
Recognizing superior clinical results for XIENCE V compared to the TAXUS® paclitaxel-eluting coronary stent system in the SPIRIT II and III randomized clinical trials, the French Health Authority (Haute Autorite de Sante) granted XIENCE V an ASA Level IV medical benefit rating (Amelioration du Service Attendu). This distinction recognizes an improved medical benefit for XIENCE V compared to TAXUS. Abbott's XIENCE V drug eluting stent will become available to all public and private hospitals throughout France in February.
"By awarding XIENCE V reimbursement and a higher medical benefit rating than previous generation drug eluting stent technology, the French Health Authority has recognized that XIENCE V represents an important advancement in treatment," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Abbott looks forward to introducing XIENCE V as a new standard of care in the treatment of coronary artery disease to physicians and patients in France."
The French Health Authority based its reimbursement evaluation for Abbott's XIENCE V drug eluting stent on the results from three randomized clinical trials: SPIRIT FIRST, SPIRIT II and SPIRIT III. In this SPIRIT family of trials, XIENCE V demonstrated:
-- Superiority for XIENCE V compared to TAXUS in the primary endpoint of
in-segment late loss at eight months in the SPIRIT III clinical
trial, with a statistically significant 50 percent reduction in late
loss for XIENCE V. In-segment late loss is a measure of vessel
renarrowing.
-- An observed 43 percent reduction in major adverse cardiac events
(MACE) compared to TAXUS at one year in SPIRIT III. MACE is an
important clinical measure of safety and efficacy outcomes for
patients, and is defined as cardiac death, heart attack (myocardial
infarction or MI), or ischemia-driven target lesion revascularization
(TLR associated with symptoms or documented lack of blood supply).
-- Non-inferiority to TAXUS with an observed 23 percent reduction in
Target Vessel Failure (TVF) for XIENCE V compared to TAXUS in the
SPIRIT III clinical trial at one year. Target Vessel Failure is a
measure of re-treatment anywhere within the target vessel and
includes cardiac death or heart attack.
-- Superiority for XIENCE V compared to TAXUS in the primary endpoint of
angiographic in-stent late loss in the SPIRIT II clinical trial at
six months. In-stent late loss is a measure of vessel renarrowing
within the margins of the stent.
"The development and availability of new and improved therapies to treat heart disease in France is critical to improving public health," said Marie-Claude Morice, M.D., Institut Cardiologique Paris Sud, Massy, France. "The availability of the XIENCE V drug eluting stent in France is in the best interests of our physicians and patients."
XIENCE V was launched in Europe and other international markets in late 2006. XIENCE V is an investigational device in the United States and Japan, and is currently under review for approval by the U.S. Food and Drug Administration.
Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.
*** It seems that the french are smarter and fairer in giving out reimbursements. They compare each DES's efficacy rather than lumping all the DES as one whole category.
Hahahahaha thats a good one....we end up using our own product???? Then hope they discover elixer of youth.... laughter is the best medicine. Your name makes me very alert and Must try to go to Novena on Monday....Serious ....and to all this is NOT an inducement or attempt to talk about religion. Respect for all race and religion.....
allright bro... this move too but in the other direction.... 
now wait for some gd news to move this fellow.... 
i think we better keep under our pillow or keep it safe.... and dont see this any more... if not sooner or later i also use their product.......
| Medtronic Media Contacts: |
Joe McGrath, Public Relations, 707-591-7367
Jeff Warren, Investor Relations, 763-505-2696
|
Medtronic Receives FDA Approval for Endeavor® Zotarolimus-Eluting Coronary Stent System
New Drug-Coated Stent Offers Excellent Combination of Safety, Effectiveness and Deliverability
MINNEAPOLIS ? Feb. 1, 2008 ?Marking a major development in the field of interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Endeavor® Zotarolimus-Eluting Coronary Stent System to be used in the treatment of coronary artery disease, which affects an estimated 13 million people in the United States and is the country?s leading cause of death.
Based on the most compelling and comprehensive body of scientific evidence submitted to the FDA for a drug-eluting stent, the approval gives U.S. cardiologists access to a new medical device for safely and effectively treating patients with narrowed coronary arteries. The Endeavor data encompasses the largest, most wide-ranging patient population submitted to the FDA in support of a drug-eluting stent, including more than 4,100 patients, followed up for as long as four years. This extensive clinical research has shown that Endeavor provides a consistent and sustained reduction in the need for repeat procedures compared to a bare-metal stent, while also maintaining an excellent safety profile. The Endeavor stent is the first new drug-eluting stent approved by the FDA since 2004.
Enabling a minimally-invasive alternative to open-heart bypass surgery, stents are tiny wire mesh tubes used to prop open coronary arteries that have been cleared of blockages to restore blood flow to the heart muscle. Drug-eluting stents deliver medication to the artery wall to reduce the chance that the artery will narrow again and require a repeat procedure.
?Endeavor represents a true next-generation drug-eluting stent because of its unique design, which combines an advanced stent platform with the potent drug zotarolimus and a biocompatible polymer,? said Dr. Martin B. Leon, professor of medicine at Columbia University Medical Center in New York, cardiologist at New York-Presbyterian Hospital/Columbia University Medical Center, founder and chairman emeritus of the Cardiovascular Research Foundation, and principal investigator of the ENDEAVOR III and IV clinical trials. ?This device addresses an important need by demonstrating comparable clinical effectiveness to a first generation drug-eluting stent while also exhibiting a safety profile more typical of a bare-metal stent, long considered a benchmark for safety performance. In addition, it has the advantage of being exceptionally easy to deliver through the tortuous vessels of the coronary vasculature. For these reasons, the Endeavor stent will undoubtedly be a welcome addition to the practice of interventional cardiology in the United States.?
The U.S. market launch of the Endeavor stent begins immediately. ?We have been strengthening our field and manufacturing capabilities in anticipation of considerable demand for the Endeavor stent in the United States,? said Scott Ward, president of the CardioVascular business at Medtronic. ?We expect to ship 100,000 units to U.S. hospitals in the next 30 days to assure full availability of this next-generation technology.?
Extensive Long-Term Clinical Evidence of Safety and Effectiveness
The ENDEAVOR clinical program includes seven studies: three randomized controlled trials and four registries. Medtronic?s FDA submission included clinical data on more than 2,100 patients treated with the Endeavor stent, 1,287 of whom were studied to two years and 675 to three years. Highlights from the program include the following results:
Excellent Safety Profile Before and After One Year
-
Presented at the FDA panel meeting in October, an analysis of pooled safety data from the ENDEAVOR clinical program reported a stent thrombosis rate for Endeavor patients of less than 1 percent within the first year and a remarkably low 0.08 percent from one year to three years post-implant. The same analysis revealed low cumulative rates of all safety measures out to three years of follow-up: stent thrombosis (0.7 percent); myocardial infarction (2.7 percent); and cardiac death (1.0 percent). Importantly, Endeavor has shown numerically fewer adverse events across all key safety measures versus a bare-metal stent. Of particular note from this analysis, just 3.5 percent of Endeavor patients experienced cardiac death or myocardial infarction through three years of follow-up, compared to 6.6 percent of patients who received a bare-metal stent.
Sustained and Consistent Reduction in the Need for Repeat Procedures
-
The Endeavor stent offers clinical effectiveness that is consistent with the current market-leading drug-eluting stent in the United States. ENDEAVOR IV, the randomized controlled trial comparing the Endeavor stent with Boston Scientific?s Taxus stent, met its primary endpoint, with a target vessel failure (TVF) rate in Endeavor patients of 6.6 percent at nine months. The TVF rate for Taxus patients at nine months was 7.2 percent. Importantly, Endeavor had similar efficacy compared to Taxus for all lesion subsets analyzed, and there were no statistically significant differences in target lesion revascularization (TLR), the clinical measure for repeat procedures.
-
Compared to a bare-metal stent in the ENDEAVOR II clinical trial, the Endeavor stent has been shown to reduce the need for repeat procedures by more than 61 percent at nine months. This treatment effect is sustained, with only 7.3 percent of Endeavor patients in this randomized controlled trial requiring a repeat procedure out to three years of follow-up.
Ultimately, the ENDEAVOR clinical program will enroll more than 22,500 patients followed to five years; approximately 16,630 of these patients will receive an Endeavor stent.
As a condition of FDA approval, Medtronic will continue its extensive post-market clinical program, which will now add sites in the United States to ensure that at least 5,000 patients are followed to a minimum of five years. In addition, Medtronic will collaborate with the FDA to conduct or participate in a study intended to identify the optimal duration of dual antiplatelet therapy following percutaneous intervention with the Endeavor drug-eluting stent.
More information for physicians and patients is available online at
www.EndeavorStent.com.
About MedtronicMedtronic, Inc. (
www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology ? alleviating pain, restoring health, and extending life for millions of people around the world.
Editor's Note: Interviews with physicians and Medtronic executives can be arranged by request. Broadcast-quality video, including soundbites and animation, is available through The News Market, www.thenewsmarket.com/medtronic, and also via satellite, Pathfire and hard copy by contacting Dan Schwartzberg at News Broadcast Network: 212-684-8910, ext. 220; dschwartzberg@newsbroadcastnetwork.com.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic?s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
- end -
Just heard over CNBC- Medtronics gets FDA approval and shares up 3 pc.....Not like in Singapore
Hahaha I like your answer Novena33
Feb. 1 (Bloomberg) -- Microsoft Corp., the world's biggest software maker, made an unsolicited offer to buy Yahoo! Inc. for about $44.6 billion, or $31 a share.
The offer is 62 percent more than Yahoo's closing stock price yesterday, according to a Microsoft statement distributed by PR Newswire. Yahoo shareholders can choose cash or stock, Microsoft said.
Maybe one day, it will be our turn?
In Spore Tax, Approved R&D will have up to 2 times tax deductible of the amount spend. I am not sure if BIG has their R&D approved. if yes, i am sure their tax deductible for FY 2007 will be alot.
These "talents" knew NOT what they were talking. Just look around at their analyses and see how many time they have got it right? They are wasting their company's payrolls and talking nonsense and always false logics.
Exactly my point. So was surprised when the local analyst from OCBC pointed out that as a result of increased expenditure which might lead conservatively to a loss for 2009, the TP was downgraded . Spoke with my friends who invests in US and they too point out that Research and Development is the key to a successful company especially after the company has received the CE mark, going forward the company will have greater potential if they still have Research ongoing......A company with no R and D may if the product is a good one make profits but most investors interested in the pharmaceutical industry are looking at new products ahead....
